Angela Vitrano

Improving survival with deferiprone treatment in patients with thalassemia major: A prospective multicenter randomised clinical trial under the auspices of the Italian Society for Thalassemia and Hemoglobinopathies

Aurelio Maggio, Angela Vitrano, Marcello Capra et al. · Blood Cells Molecules and Diseases · 2009 · 96 citations

Medicine, Hematology, Pharmacology +6

Evaluation of the efficacy and safety of deferiprone compared with deferasirox in paediatric patients with transfusion-dependent haemoglobinopathies (DEEP-2): a multicentre, randomised, open-label, non-inferiority, phase 3 trial

Aurelio Maggio, Antonis Kattamis, Mariagrazia Felisi et al. · The Lancet Haematology · 2020 · 72 citations

Medicine, Pediatrics, Pharmacology +11

Long‐term sequential deferiprone–deferoxamine <i>versus</i> deferiprone alone for thalassaemia major patients: a randomized clinical trial

Aurelio Maggio, Angela Vitrano, Marcello Capra et al. · British Journal of Haematology · 2009 · 70 citations

Medicine, Pharmacology, Pharmacotherapy +14

The era of comparable life expectancy between thalassaemia major and intermedia: Is it time to revisit the major‐intermedia dichotomy?

Angela Vitrano, Giuseppina Calvaruso, Eliana Lai et al. · British Journal of Haematology · 2016 · 56 citations · Full text

Medicine, Hematology, Internal Medicine +12

Survival and causes of death in 2,033 patients with non-transfusion-dependent β-thalassemia

Khaled M. Musallam, Angela Vitrano, Antonella Meloni et al. · Haematologica · 2021 · 51 citations · Full text

Medicine, Hematology, Transfusion Medicine +6